Allergy Therapeutics plc
AGYTF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 22.1% | 57.3% | -35.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 32.8% | 61.3% | 42.6% | 61.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -47.1% | -25.3% | -108.1% | -35.4% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -96% | -32.6% | -113.6% | -46.6% |
| EPS | -0.008 | -0.002 | -0.005 | -0.006 |
| % Growth | -265.2% | 55.8% | 10.3% | – |
| EPS Diluted | -0.008 | -0.002 | -0.005 | -0.006 |
| Weighted Avg Shares Out | 5 | 5 | 5 | 3 |
| Weighted Avg Shares Out Dil | 5 | 5 | 5 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | -$0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -87.3% | -12.2% | -105.5% | -27.9% |